期刊文献+

18F-FDG PET/CT显像最大标准化摄取值(SUVmax)与肺腺癌及其亚型EGFR突变的相关性 被引量:4

Correlation between F-FDG PET/CT maximum standardized uptake value and epidermal growth factor receptor mutation status in pulmonary adenocarcinoma and its different histologic subtypes
下载PDF
导出
摘要 目的探讨18F-FDG PET/CT显像最大标准化摄取值(18F-FDG maximum standardized uptake value,SUVmax)与肺腺癌及其不同组织学亚型表皮生长因子受体(epidermal growth factor receptor,EGFR)突变之间的相关性。方法回顾性分析305例经病理证实为肺腺癌患者的PET/CT图像与临床病理学资料,包括年龄、最大径、性别、吸烟史、是否转移、分期、组织学亚型及分化程度。通过单因素和多因素Logistic回归分析方法,得出纳入分析的变量中与EGFR突变相关的因素,并制作计分量表预测EGFR突变状态。结果EGFR整体突变率为63.6%(194/305),EGFR突变与女性(72.9%vs.54.0%,P=0.001)、不吸烟(68.2%vs.46.0%,P=0.001)、SUVmax≤5.5(75.2%vs.57.1%,P=0.006)及中低危分组(67.4%,65.2%vs.44.9%,P=0.012)显著相关。计分量表得分与EGFR突变显著相关(P<0.001),ROC定义得分>2为最佳截断值,敏感度、特异度及准确度分别为64.4%、59.6%及62.6%。结论PET/CT对EGFR突变有一定的预测价值,接合患者的临床病理资料和SUVmax,则预测价值更高。 Objective To investigate the relationship between18 F-FDG maximum standardized uptake value(SUVmax)and epidermal growth factor receptor(EGFR)mutation in pulmonary adenocarcinoma and its different histologic subtypes.Methods The PET/CT imaging and clinicopathological data of 305 patients with lung adenocarcinoma confirmed by pathology were retrospectively analyzed.Clinicopathological data included age,diameter,gender,smoking status,metastasis,stage,pathological subtypes and differentiate grade.The factors related to EGFR mutation were analyzed by univariate and multivariate Logistic regression analysis.The scoring scale was made to predict EGFR mutation status.Results The overall mutation rate of EGFR was 63.6%(194/305).EGFR mutation was significantly correlated with women(72.9%vs.54.0%,P=0.001),non-smoking(68.2%vs.46.0%,P=0.001),SUVmax≤5.5(75.2%vs.57.1%,P=0.006),and low and medium risk groups(67.4%,65.2%vs.44.9%,P=0.012).The score of the scoring scale was significantly correlated with EGFR mutation(P<0.001),and the score>2 was defined as the optimal cut-off value of the ROC curvewith sensitivity of 64.4%,specificity of 59.6%and accuracy of 62.6%.Conclusion PET/CT has certain predictive value for EGFR mutation,and its predictive value is higher by combining clinic opathological data of patients with SUVmax.
作者 胡冰心 肖杰 付哲荃 程登峰 修雁 石洪成 HU Bing-xin;XIAO Jie;FU Zhe-quan;CHENG Deng-feng;XIU Yan;SHI Hong-cheng(Department of Nuclear Medicine,Zhongshan Hospital,Fudan University,Shanghai 200032,China)
出处 《复旦学报(医学版)》 CAS CSCD 北大核心 2020年第4期554-559,共6页 Fudan University Journal of Medical Sciences
关键词 18F-FDG 肺腺癌 组织亚型 表皮生长因子受体(EGFR) 计分量表 18F-FDG pulmonary adenocarcinoma histologic subtype epidermal growth factor receptor(EGFR) scoring scale
  • 相关文献

参考文献6

二级参考文献42

  • 1王淑侠,徐卫平,李东江,侯庆仪,乔穗宪,唐安戊.从标准摄取值预测肿瘤的侵袭性:206例肺癌PET分析[J].中国医学影像技术,2006,22(5):770-772. 被引量:6
  • 2Antoch G,Stattaus J,Nemat AT,et al.Non-small cell lung cancer:dual-modality PET/CT in preoperative staging[J].Radiology,2003,229(2):526-533.
  • 3Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/american thoracic society/european re- spiratory society international muhidisciplinary classification of lung adenocarcinoma[J]. J Thorac Oncol, 2011, 6(2):244-285. doi: 10. 1097/JTO. 0b013e318206a221.
  • 4Lardinois D, De Leyn P, Van Schil P, et al. ESTS guidelines for in- traoperative lymph node staging in non-small cell lung cancer [ J ].Eur J Cardiothorac Surg, 2006, 30(5):787-792.
  • 5Russell PA, Wainer Z, Wright GM, et al. Does lung adenocarcino- ma subtype predict patient survival?: A clinicopathologic study based on the new International Association for the Study of Lung Cancer/A- merican Thoracic Society/European Respiratory Society international muhidiseiplinary lung adenoearcinoma classification [ J ]. J Thorac Oncol, 2011, 6 ( 9 ): 1496-1504. doi: 10. 1097/JTO. 0bO13e318221 f701.
  • 6Sica G, Yoshizawa A, Sima CS, et al. A grading system of lung ade- based on histologic pattern is predictive of disease re- currence in stage I tumors[J]. Am J Surg Pathol, 200, 34(8) : 1155-1162. doi : I0. 1097/PAS. 0b013e3181 e4ee32.
  • 7Vallires E, Shepherd FA, Crowley J, el al. The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming ( sev- enth) edition of the TNM classification for lung cancer[ J]. J Thorac Oncol, 2009, 4 ( 9 ): 1049-1059. doi: 10. 1097/JTO. 0b013e3181 b27799.
  • 8Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-pa- clitaxel in pulmonary adenocarcinoma[ J]. N Engl J Med, 2009, 361 ( 10 ) :947-957. doi : 10. 1056/NEJMoa0810699.
  • 9Kerr KM. Pulmonary adenocarcinomas: classification and reporting [ J]. Histopathology, 2009, 54 ( 1 ) : 12-27. doi: 10. 1111/j. 1365- 2559. 2008. 03176. x.
  • 10Yoshizawa A, Motoi N, Riely G J, et al. Impact of proposed IASLC/ ATS/ERS classification of lung adenocarcinoma: prognostic sub- groups and implications for further revision of staging based on analy- sis of 514 stage I cases[J]. Mod Pathol, 2011, 24(5) : 653-664. doi : 10. 1038/modpathol. 2010. 232. 3.

共引文献27

同被引文献50

引证文献4

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部